161 related articles for article (PubMed ID: 34842037)
1. Incidence and prophylaxis of herpes zoster in relapsed or refractory B-cell lymphoma patients after CD19-specific CAR-T cell therapy.
Liu H; Li P; Zhao A; Lei W; Liang A; Qian W
Leuk Lymphoma; 2022 Apr; 63(4):1001-1004. PubMed ID: 34842037
[No Abstract] [Full Text] [Related]
2. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of chimeric antigen receptor T-cell therapy targeting CD19/CD22 in refractory/relapsed transformed aggressive B-cell lymphoma.
Xu H; Lv Q; Huang L; Cao W; Wang J; Meng F; Li C; Zheng M; Chen L; Mu K; Cheng J; Zhu L; Zhou J; Zhang Y; Wang N; Cao Y
Cytotherapy; 2023 Feb; 25(2):185-191. PubMed ID: 36283943
[No Abstract] [Full Text] [Related]
4. Selection process and causes of non-eligibility for CD19 CAR-T cell therapy in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma in a European center.
Carpio C; Iacoboni G; Villacampa G; Catalá E; Bobillo S; Pérez A; Jiménez M; Segura L; Olivé M; Farriols A; Abrisqueta P; Valcárcel D; Carreras MJ; Bosch F; Barba P
Leuk Lymphoma; 2021 Sep; 62(9):2288-2291. PubMed ID: 33899648
[No Abstract] [Full Text] [Related]
5. Improving the safety of CAR-T-cell therapy: The risk and prevention of viral infection for patients with relapsed or refractory B-cell lymphoma undergoing CAR-T-cell therapy.
Qian H; Yang X; Zhang T; Zou P; Zhang Y; Tian W; Mao Z; Wei J
Am J Hematol; 2024 Apr; 99(4):662-678. PubMed ID: 38197307
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
Cappell KM; Sherry RM; Yang JC; Goff SL; Vanasse DA; McIntyre L; Rosenberg SA; Kochenderfer JN
J Clin Oncol; 2020 Nov; 38(32):3805-3815. PubMed ID: 33021872
[TBL] [Abstract][Full Text] [Related]
7. Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma.
Strati P; Neelapu SS
Curr Oncol Rep; 2019 Mar; 21(5):38. PubMed ID: 30919158
[TBL] [Abstract][Full Text] [Related]
8. CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives.
Mohty M; Gautier J; Malard F; Aljurf M; Bazarbachi A; Chabannon C; Kharfan-Dabaja MA; Savani BN; Huang H; Kenderian S; Nagler A; Perales MA
Leukemia; 2019 Dec; 33(12):2767-2778. PubMed ID: 31690821
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis.
Zhou H; Luo Y; Zhu S; Wang X; Zhao Y; Ou X; Zhang T; Ma X
BMC Cancer; 2018 Sep; 18(1):929. PubMed ID: 30257649
[TBL] [Abstract][Full Text] [Related]
10. Reader Response: Long-term Neurologic Safety in Patients With B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
Tan BJ; Chan LL; Tan EK
Neurology; 2023 Apr; 100(14):688. PubMed ID: 37012060
[No Abstract] [Full Text] [Related]
11. Chimeric antigen receptor modified T cell therapy in B cell non-Hodgkin lymphomas.
Levin A; Shah NN
Am J Hematol; 2019 May; 94(S1):S18-S23. PubMed ID: 30652353
[TBL] [Abstract][Full Text] [Related]
12. Reader Response: Long-term Neurologic Safety in Patients With B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
Karschnia P; Rejeski K; Subklewe M; von Baumgarten L
Neurology; 2023 Apr; 100(14):687-688. PubMed ID: 37012062
[No Abstract] [Full Text] [Related]
13. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
14. Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma.
Tong C; Zhang Y; Liu Y; Ji X; Zhang W; Guo Y; Han X; Ti D; Dai H; Wang C; Yang Q; Liu W; Wang Y; Wu Z; Han W
Blood; 2020 Oct; 136(14):1632-1644. PubMed ID: 32556247
[TBL] [Abstract][Full Text] [Related]
15. Radiation therapy for patients with relapsed or refractory mantle cell lymphoma undergoing CD19-targeted chimeric antigen receptor T-cell therapy.
Ababneh HS; Frigault MJ; Patel CG
Hematol Oncol; 2024 Jan; 42(1):e3221. PubMed ID: 37679941
[No Abstract] [Full Text] [Related]
16. Chimeric Antigen Receptor T-Cell Therapies for Aggressive B-Cell Lymphomas: Current and Future State of the Art.
Abramson JS; Lunning M; Palomba ML
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():446-453. PubMed ID: 31099671
[TBL] [Abstract][Full Text] [Related]
17. Anti-CD19 CAR T-Cell Therapy for B-Cell Non-Hodgkin Lymphoma.
Abramson JS
Transfus Med Rev; 2020 Jan; 34(1):29-33. PubMed ID: 31677848
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas.
Srour SA; Singh H; McCarty J; de Groot E; Huls H; Rondon G; Qazilbash M; Ciurea S; Bardelli G; Buck J; Alousi A; Nieto Y; Rezvani K; Marin D; Popat U; Hosing C; Shpall EJ; Wierda WG; Kantarjian H; Champlin RE; Cooper LJ; Kebriaei P
Blood; 2020 Mar; 135(11):862-865. PubMed ID: 31961918
[No Abstract] [Full Text] [Related]
19. Efficacy and safety of chimeric antigen receptor T cell immunotherapy in B-cell non-Hodgkin lymphoma: a systematic review and meta-analysis.
Wang N; Meng Y; Wu Y; He J; Liu F
Immunotherapy; 2021 Mar; 13(4):345-357. PubMed ID: 33406914
[No Abstract] [Full Text] [Related]
20. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.
Aamir S; Anwar MY; Khalid F; Khan SI; Ali MA; Khattak ZE
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e334-e347. PubMed ID: 33573914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
